ANVS Stock Summary and Trading Ideas (Annovis Bio | NYSE:ANVS)

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.

Annovis Bio trades on the NYSE stock market under the symbol ANVS.

As of April 25, 2024, ANVS stock price climbed to $13.26 with 125,145 million shares trading.

ANVS has a beta of 0.70, meaning it tends to be less sensitive to market movements. ANVS has a correlation of 0.01 to the broad based SPY ETF.

ANVS has a market cap of $146.01 million. This is considered a Micro Cap stock.

In the last 3 years, ANVS stock traded as high as $132.00 and as low as $5.42.

The top ETF exchange traded funds that ANVS belongs to (by Net Assets): VTI, VXF, IWC.

ANVS stock has underperformed the market in the last year with a return of -10.5%, while SPY returned +22.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ANVS shares. However, ANVS has outperformed the market in the last 3 month and 2 week periods, returning +45.9% and +12.9%, while SPY returned +3.4% and -2.7%, respectively. This indicates ANVS has been having a stronger performance recently.

ANVS support price is $11.96 and resistance is $13.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANVS stock will trade within this expected range on the day.